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Abstract
The hepatitis delta virus (HDV) is a small RNA virus that encodes a single protein 
and which requires the hepatitis B virus (HBV)-encoded hepatitis B surface 
antigen (HBsAg) for its assembly and transmission. HBV/HDV co-infections exist 
worldwide and show a higher prevalence among selected groups of HBV-infected 
populations, specifically intravenous drug users, practitioners of high-risk sexual 
behaviours, and patients with cirrhosis and hepatocellular carcinoma. The chronic 
form of HDV-related hepatitis is usually severe and rapidly progressive. Patterns 
of the viral infection itself, including the status of co-infection or super-infection, 
virus genotypes (both for HBV and HDV), and persistence of the virus’ 
replication, influence the outcome of the accompanying and manifested liver 
disease. Unfortunately, disease severity is burdened by the lack of an effective 
cure for either virus type. For decades, the main treatment option has been 
interferon, administered as mono-therapy or in combination with nucleos(t)ide 
analogues. While its efficacy has been reported for different doses, durations and 
courses, only a minority of patients achieve a sustained response, which is the 
foundation of eventual improvement in related liver fibrosis. The need for an 
efficient therapeutic alternative remains. Research efforts towards this end have 
led to new treatment options that target specific steps in the HDV life cycle; the 
most promising among these are myrcludex B, which inhibits virus entry into 
hepatocytes, lonafarnib, which inhibits farnesylation of the viral-encoded L-
HDAg large hepatitis D antigen, and REP-2139, which interferes with HBsAg 
release and assembly.
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Core Tip: The hepatitis delta virus (HDV) is a small defective virus, of interest to 
scientists for its replicative reliance on and ability to inhibit the common hepatitis B 
virus (HBV). HDV infection occurs worldwide but shows some geographic variation 
and its prevalence is generally underestimated. HDV/HBV co-infection causes severe 
liver disease and the persistence of viral replication is associated with poor prognosis, 
although interferon is effective in around a quarter of patients. Improved understanding 
of the HDV life cycle has led to identification of specific antiviral targets and new 
drugs, including inhibitors of the sodium tauro-cholate cotransporting polypeptide 
receptor and farnesyltransferase.
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The hepatitis delta virus (HDV) is a defective virus that survives in the host by 
enveloping itself with the hepatitis B surface antigen (HBsAg) provided by the 
hepatitis B virus (HBV)[1]. This unique virus was discovered in 1977 by Rizzetto et al
[2] following description of the delta antigen in HBsAg carriers. The subsequent 
research uncovering HDV modes of replication and its interactions with HBV have 
provided information with clinical implications[3]. HDV is highly infectious and 
induces a heterogeneous liver disease that rapidly progresses to cirrhosis; the outcome 
itself is influenced by several viral and host factors, including virus genotypes and 
level of viremia (for both HDV and HBV) as well as the presence of any concomitant 
causes of liver damage[3]. According to recent reports, 10.58% of general HBV-positive 
individuals have co-infection with HDV, excluding the intravenous drug users 
(IVDUs) and practitioners of high-risk sexual behaviours (HRSBs)[4].
Collectively, these data highlight the need for HDV screening and control strategies, 
which must be developed rationally. In the industrialized world, the decline of new 
infections has regrettably reduced awareness and testing for HDV[1,5]. Moreover, 
there is a significant lacuna in the literature, with limited data reported from the 
Americas, Southern Africa and Asia[4], although reliable data from across the globe 
are required to overcome this pathogenic threat. Once HDV infection is diagnosed, the 
greatest challenge to clinical care is related to the treatment of associated liver disease. 
Interferon (IFN) treatment has been the only pharmacological option for decades but 
its efficacy remains unsatisfactory[6]. The perseverance of HDV researchers is 
beginning to pay off, however, with enhanced knowledge on the viral life cycle 
leading to development of drugs targeting specific steps in such, several of which are 
now under advanced clinical evaluation[6-8].
VIROLOGY
HDV is similar to viroids and virusoids in its structure and replication process but it 
presents a distinctive identity. Accordingly, HDV was classified as the sole member of 
the Deltaviridae genus[1,9]. The virus contains about 1700 nucleotides and has a 
circular structure that is formed by base-pairing involving 74% of its genomic RNA. It 
encodes a single protein - the delta antigen (HDAg) — which combines with the HDV 
genome to form a ribonucleoprotein complex (referred to as an RNP). The RNP 
becomes enveloped upon interaction with HBV, which serves as a helper virus, 
providing the HBsAg component. The latter is necessary for HDV assembly, release 
and transmission, but it is not required for any of the other steps in replication[3,10]. 
HDAg is present in two isoforms: small (S-HDAg) and large (L-HDAg), each carrying 
out a specific role in the HDV life cycle. S-HDAg is composed of 195 amino-acids and 
promotes RNA replication, while L-HDAg is composed of 214 amino-acids and is 
essential for the virion packaging. The isoforms differ by 19 amino-acids located in the 
C-terminal region of L-HDAg exclusively, the presence of which results from an 
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editing process that is regulated by the adenosine deaminase enzyme ADAR1[11]. 
HDAg modification occurs at the post-transcriptional level, similar to the well-known 
processes of phosphorylation, acetylation, methylation and isoprenylation, all of which 
regulate the hepatitis viral life cycles (Figure 1).
HDV replicates exclusively in the liver, inside hepatocyte nuclei. The virus uses the 
same entry mechanism as HBV, being enveloped by HBsAg, differentiated in the small 
(S-HBsAg), large (L-HBsAg) and medium (also known as M-HBsAg) forms. After 
ligating the hepatocyte’s surface heparan sulphate proteoglycans (commonly referred 
to as HSPGs), the pre-S1 domain of L-HBsAg binds to the receptor for HBV, identified 
as the sodium tauro-cholate cotransporting polypeptide (NTCP)[12]. The viral RNP 
then translocates into the nucleus, where its genomic RNA is transcribed first into the 
complementary antigenomic RNA, then into new genomic RNA and mRNA by the 
host’s RNA polymerase II enzyme. The fact that HDV does not encode its own RNA 
polymerase enzyme but redirects the host’s is a further peculiarity of this hepatitis 
virus.
Once linear polymers are produced in the HDV-infected hepatocyte, they self-cleave 
via a ribozyme activity of the virus and then circularize. The viral mRNA then 
migrates from the nucleus to the cytoplasm, for subsequent synthesis of either S-
HDAg or L-HDAg. The protein products associate with the viral genomic RNA to 
form new ribonucleoproteins, each of approximately 20 nm in diameter. This complex 
relies on HBV surface antigens for complete formation and subsequent secretion[13]. 
The latter process occurs only after a farnesylation process[14], which makes molecules 
more lipophilic, whereby L-HDAg interacts with HBsAg at the endoplasmic 
reticulum.
While at first evaluation this entire process appears rudimentary, HDV has evolved 
a complex and unusual replicative mechanism, intriguing for researchers but proving 
a challenge to fully elucidate. It has been proposed, in the field of innovative research, 
that viruses other than HBV, such as flavivirus and hepacivirus, could package the 
HDV ribonucleoprotein[15]. This unconventional transmission of HDV certainly 
requires confirmation in a human system; however, the newest knowledge on its 
interaction with the NTCP receptor[12] and the farnesylation process of L-HDAg[14] 
has led to new therapeutic proposals.
EPIDEMIOLOGY
Sero-epidemiological studies performed between the 1980s and 1990s estimated the 
HDV prevalence among HBsAg-positive patients to be 5%, equating to about 20 
million people worldwide[3,16]. Regional prevalence of HDV infection was higher in 
South Europe, Middle East, East Africa and Asia, with relatively lower rates in 
Northern Europe, South Africa and North America[17]. During the more recent 2000s 
and 2010s, the introduction of HBV vaccination, institution of preventive measures 
and improvements in hygiene habits have led to decreases in HDV prevalence rates in 
multiple regions. In Taiwan, for example, HDV prevalence among HBsAg-positive 
subjects declined substantially, from 24% in 1983 to 4% in 1995[18], while in Italy, it 
declined from 23% in 1987 to 14% in 1992 to 8% in 1997[19]. However, in parallel with 
the decreased prevalence rates in previously endemic areas, other HDV hot zones 
emerged, including South Eastern Russia, Northern India, Vietnam and Albania.
Moreover, starting in the early 2000s, immigration activities have prompted a new 
rise in HDV prevalence in some European States, following a large influx of 
immigrants from endemic areas, such as Romania, the ex-Soviet Union and North 
Africa[20]. France also experienced a remarkable increase in cases, reaching a rate of 
6.5% in 2010 after remaining stable at around 1% from 1997 to 2005[21]. Similarly, 
Germany showed an initial decline during the 1990s (from 19% to 7%) but then 
experienced an upswing trend, with rates fluctuating between 8% and 14%, in the 
2000s[22].
Nowadays, HDV infection maintains its worldwide distribution. According to two 
recent systematic reviews, global prevalence is around 0.16%-0.98% among the general 
population and 4.5%-14.6% among HBsAg-positive subjects[4,23]. Geographic 
variations are still present, considering both the overall population and HBV carriers. 
Among the general population worldwide, Mongolia has reported the highest HDV 
prevalence[4], with primacy among HBsAg-positive people (prevalence rate of 36.9%). 
However, prevalence rates greater than 10% are also reported by Moldova and 
Western and Middle African countries[23]. According to demographical character-
istics, men are slightly more affected than women[4] and the elderly are at greater risk 
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Figure 1 Schematic representation of the hepatitis D virus life cycle. New drugs interfere with the hepatitis B surface antigen at the viral entry or viral 
assembly level. HBsAg: Hepatitis B surface antigen; HDAg: Hepatitis D antigen; HDV: Hepatitis delta virus; L-HDAg: Large hepatitis D antigen; NTCP: Sodium tauro-
cholate cotransporting polypeptide; RNP: Ribonucleoprotein complex; S-HDAg: Small hepatitis D antigen.
than the young (80% among those ≥ 50-years-old vs 3% among those < 30-years-old)
[24].
Among the eight recognized HDV genotypes (identified as 1-8), genotype 1 is the 
most common and it is present worldwide[23,25]. The other seven genotypes are more 
localized, with genotypes 2 and 4 mainly confined to Asia, genotype 3 to Latin 
America and genotypes 5-8 to Africa[23].
As exposure to blood of infected subjects is the predominant route of HDV 
transmission, some groups of high-risk people have been identified. Most HDV-
infected patients are IVDUs, who had been infected upon needle-stick injury or use of 
contaminated syringes[26]. The reported prevalence rates among this subgroup range 
from 21%[27] to 36%[28], with a pooled odds ratio (OR) of 19.0[23]. Another group of 
high-risk individuals are practitioners of HRSBs, including commercial sex workers 
and promiscuous homosexuals[26], among whom the reported prevalence reaches up 
to 11%[29], with a pooled OR of 18.7[23]. The risk of infection is also higher among the 
human immunodeficiency virus-positive population (pooled OR: 6.6) and 
haemodialytic patients (pooled OR: 3.4)[23]. Nowadays, nosocomial infection and 
transfusion transmission occur less frequently than in the past. However, some 
cultural practices, such as tattoos and piercing, are quickly becoming an appreciable 
route of transmission[30].
Taken together, these data show that the global presence of HDV infection has not 
decreased and it is probably still underestimated.
CLINICAL MANIFESTATIONS AND DIAGNOSIS
Viremia, genotypes and liver disease
The replicative activity of HDV can influence the course of liver disease[31].
A multicentre study found that subjects with persistent HDV replication had worse 
prognosis in terms of liver failure, need for liver transplantation and/or death than 
those with undetectable HDV-RNA[32]. On the other hand, the few patients in whom 
HDV-RNA had become undetectable during their follow-up were determined to be 
less likely to develop liver cirrhosis than those with persistently positive HDV-RNA 
levels[32].
To date, little is known about the determinants of spontaneous clearance of HDV-
RNA, despite the early clearance of HDV infection being one of the main parameters 
determining prognosis of the related liver disease[10,33].
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Although HBV replication is usually suppressed in the presence of HDV infection, 
high levels of HBV viremia are associated with more severe liver damage[34]. In 
addition, HBV genotypes may also play a role in the course of chronic hepatitis D 
(CHD), which is considered the most severe and rapidly progressive form of chronic 
viral hepatitis[3].
Besides host-related factors, other viral factors might be involved in clearance of the 
virus. One such factor is genotypic variability. Among the eight known genotypes, 
HDV-1 has the highest pathogenic potential[31,33,35], while HDV-2 and HDV-4 are 
associated with milder forms of the disease[35]. According to a study conducted in 
Taiwan, patients infected with HDV-2 develop liver failure less frequently than those 
with genotype 1[34]. HDV-3 has been associated with an increased risk of fulminant 
hepatitis[3,36], whereas HDV-5 has a better prognosis than HDV-1[33]. The pathogenic 
properties of HDV 5-8 are not well characterized[7,36]. Among the spectrum of host 
and viral factors that may underlie the different outcomes of infection with these 
various genotypes, we can include variability in virus replication and virion assembly 
efficacy, both of which contribute to the rate of HDV virion secretion, and such host 
factors as race or presence of single-nucleotide polymorphisms[35].
Clinical manifestation and outcomes of the hepatitis D disease differ according to 
the HDV acquisition modality, itself depending on HBsAg status of the infected 
individual. In HBV/HDV co-infections, the presence of both viruses causes wide 
hepatic necrosis, bringing about severe or occasionally fulminant hepatitis[37]. Acute 
hepatitis can occur either with a single peak of disease (mono-phasic) or with two 
distinct peaks (biphasic). In the latter case, the first peak matches to an initial HBV 
spread, and the second peak to HDV propagation[7,37]. The HBV/HDV co-infection 
usually leads to a self-limited acute hepatitis; indeed, only 2% of patients with co-
infection progress to cirrhosis[3,38-41]. The diagnosis of co-infection is confirmed by 
the simultaneous presence of serological markers for primary HBV and HDV 
infections[37]. Generally, the first of these to appear are the host’s antibody to hepatitis 
B core protein (anti-HBc IgM), while that to hepatitis D (anti-HD IgM) appears within 
2 wk from clinical onset, usually remaining detectable for up to 5-6 wk afterwards. The 
anti-HD IgG antibody reaches a detectable level after the IgM antibodies disappear, 
and may persist for months or even years. A failure in anti-HD IgM clearance predicts 
the chronicity of hepatitis[26,35,42].
Conversely, in HDV super-infection, the virus infects individuals with chronic HBV 
infection, and it typically leads to HDV persistence with development of cirrhosis[35]. 
It may present either as an exacerbation of a known chronic hepatitis B status 
accompanied by hepatic decompensation, or as a new acute hepatitis status in 
asymptomatic HBsAg carriers[35]. Super-infection usually leads to a chronic infection 
(in > 90% of cases), with rapid progression to cirrhosis[23,38-40]. Diagnosis of the 
super-infection is based upon a positive test for anti-HD IgM and a negative test for 
anti-HBc IgM in HBsAg carriers[35,37]. The super-infection itself is characterized by 
early presence of HDV-RNA and HDV antigen, followed by increase in anti-HD IgM 
that remains persistently detectable, in parallel with development of chronicity. In 
addition, during the acute phase, there is a suppression of HBV replication[35].
CHD
Among chronic viral hepatitis, CHD is distinguished by its severity and higher risk of 
evolution. It involves a 3-fold increase in the risk of cirrhosis and a 2-fold increase in 
the risk of death, as compared to HBV and hepatitis C virus infection alone[3,7,35,39,
43]. Half of the patients with CHD have experienced a previous acute hepatitis attack, 
which often represents the time of super-infection with HDV. Clinically, CHD can 
range from asymptomatic forms, which are discovered incidentally, to symptomatic 
ones, manifested as fatigue, malaise, and anorexia[3,35]. Diagnosis is achieved upon 
detection of high titres of anti-HD IgG and IgM in serum, whereas the HD antigen 
remains persistently detectable in the liver[35]. Typically, alanine aminotransferase 
(ALT) levels remain stably elevated or fluctuate, reflecting the destruction of hepatic 
cells. The lowering of such levels is usually meaningful for tracking disease 
progression to cirrhosis[35,44].
Cirrhosis
The main complication of chronic hepatitis is the development of cirrhosis. Cirrhosis 
occurs in 70% of cases within 5 to 10 years after hepatitis development, but in 15% of 
patients it may occur within 1 year to 2 years[7,37]. While the precise mechanism of 
this progression remains unknown, it has been proposed that the long form of HDAg 
may stimulate liver fibrosis through interaction with transforming growth factor-β-
induced signal activation[35].
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Despite liver biopsy remaining the gold standard procedure for diagnosis and 
staging of cirrhosis, there are validated (and less invasive) predictive scoring systems 
applicable to patients with HDV disease. The Delta-4 fibrosis score uses gamma-
glutamyl transferase (commonly referred to as GGT), ALT, platelet count, and liver 
stiffness as parameters[45]. A similar score called the “delta Fibrosis Score” considers 
GGT along with age, albumin and serum cholinesterase[46]. Abbas et al[40] proposed 
to simply use spleen size and platelet count as the predictive parameters of cirrhosis. 
Other non-invasive markers of fibrosis that are in use clinically include components of 
the extracellular matrix, namely procollagen III N-peptide, collagen IV, and hyaluronic 
acid; however, these factors have lower diagnostic accuracy than in other forms of 
chronic hepatitis[35].
Once HDV cirrhosis is established, it can remain asymptomatic or induce non-
specific symptoms, such as muscle weakness and jaundice. In the advanced stage, it 
can also evolve complications[37]. In half of the cases, these complications occur 
within 8 years and include portal hypertension, abdominal ascites, gastrointestinal 
bleeding and hepatic encephalopathy[31,44]. On average, the annual incidence of liver 
decompensation in cirrhosis ranges from 2.6% to 3.6%, being more than doubled 
compared to HDV-negative hepatitis B cases[3,44,47]. Among HDV-positive patients, 
mortality from cirrhosis and hepatocellular carcinoma (HCC) is higher than that for 
patients with HBV infection alone[23,44,48].
HCC
HCC is a frequent cause of death from cancer worldwide, and its incidence and 
mortality rates remain on an upward trajectory. The estimated annual incidence of 
HCC ranges from 2.6% to 2.8%[26,47]. Chronic viral hepatitis, particularly related to 
hepatitis B, C and D viruses, is responsible for more than 80% of all cases of HCC[43,
49]. While both HBV and hepatitis C virus have already been classified by the World 
Health Organization as oncogenic viruses, the role of HDV infection in HCC 
development is still under debate[43,48].
Previous studies have shown that the incidence of HCC was similar among patients 
with HDV and HBV chronic infections, suggesting that HDV is not a contributory 
factor, per se, to the carcinogenic process. Contrariwise, recent lines of evidence from 
cohort studies have shown a significantly increased risk of HCC among patients with 
HDV liver disease, which suggests a greater extent of correlation to HDV than to HBV 
replication[26,43,48,50,51].
Some studies have estimated that between 16.7% and 20% of cirrhosis or HCC cases 
among people with hepatitis B worldwide are attributable to HDV infection[23]. 
Nevertheless, the mechanisms of HCC development in HDV-infected patients remain 
debated[37]. Bockmann et al[48] suggest that the high rate of HCC was caused by the 
rapid progression to liver cirrhosis and not by viral activity at baseline. In addition, 
experiments in transgenic mice expressing HDAg proteins seem to rule out a direct 
carcinogenic role of HDV[3]; however, the L-HDAg may promote oxidative stress 
through activation of signal transducer and transcription-3 and nuclear factor-kappa B, 
factors vital to cancer cell communication and carcinogenesis. Moreover, it may also 
promote cancer cell survival through epigenetic mechanisms, such as DNA 
methylation of the tumour suppressor gene and acetylation of histone H3 of the 
clustering promoter[40].
TREATMENT 
HDV infection with related liver disease is difficult to treat. Drugs for HBV cure are 
generally not effective on HDV, and the absence of its own polymerase for the latter 
complicates attempts to identify suitable therapeutic targets. The ever popular IFN-
based therapy was introduced about 35 years ago. Pegylated (Peg)-IFN-α is now 
preferred over the standard formulation, according to its comparatively improved 
efficacy and safety. This underlies the biochemical and virological responses that are 
achieved in about 25% of treated patients[47], with response usually being evaluated 
clinically at 6 mo post-treatment. Guidelines from the European Association for Study 
of the Liver recommend Peg-IFN for 48 wk (Table 1) in patients with compensated 
liver disease and nucleos(t)ide analogues for HBV/HDV patients if HBV replication is 
above 2000 IU/mL[52]. In the last decade, articles published on the HDV have 
addressed numerous questions related to the role of combination therapy, to the 
optimal dose and duration of PEG-IFN administration, and to the real end-points of 
HDV treatment as well as the clinical benefit.
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Table 1 Established and undergoing drugs in the management of hepatitis delta virus chronic hepatitis
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HDV: Hepatitis delta virus; NTCP: Sodium tauro-cholate cotransporting polypeptide; Peg-IFN: Pegylated interferon; ALT: Alanine aminotransferase; 
HBsAg: Hepatitis B surface antigen.
Strategies to improve the efficacy of Peg-IFN-α
In a large randomized controlled study - the Hep-Net-International Delta Hepatitis 
Intervention Trial (also referred to as the HIDIT-1) - performed by the German 
Network, 90 patients were assigned to receive weekly treatment with either 180 µg of 
Peg-IFN-α plus 10 mg of adefovir (31 patients), 180 µg of Peg-IFN-α plus placebo (29 
patients), or 10 mg of adefovir alone (30 patients) for 48 wk[53]. Twenty-four weeks 
after the treatment initiation, a sustained HDV-RNA clearance was observed in 28% of 
the patients who had been treated with Peg-IFN-α either as mono-therapy or in 
combination with adefovir; no therapeutic effect was observed in the group treated 
with adefovir alone. The HIDIT-2 study[54] embodied a second attempt to clarify if 
combination therapy was superior to Peg-IFN-α alone in treatment of HDV patients, 
but this time examining tenofovir use. In that trial[54], 120 patients with HDV-RNA 
positivity were randomized to receive either Peg-IFN-α plus tenofovir or Peg-IFN-α 
plus placebo for 96 wk. At the end of therapy, viremia was negative in 48% of patients 
on combination therapy and in 33% of those on the Peg-IFN-α mono-therapy[54]. At 
week 24 post-therapy, virological response was observed in less than 30% of patients. 
The combination therapy with tenofovir did not provide benefits in HDV patients with 
low HBV-DNA levels, not even when 96 wk of the Peg-IFN-α regimen was compared 
to 48 wk. However, more side-effects were associated to the prolonged therapy, 
having consequence for the most advanced form of liver disease.
While other studies have also suggested no clear benefit in extending Peg-IFN-α 
treatment, positive results were obtained from a retrospective study that included 99 
patients, with a median treatment duration of 24 mo and post-treatment follow-up of 
55 mo[55]. Altogether, however, the previous studies have recognized the efficacy of 
IFN in about one-third of treated patients[56]. Yet, the optimal treatment duration 
remains to be defined and the addition of nucleos(t)ide analogues does not seem to 
improve the result[57,58].
Predictors of long-term response to IFN
Fifty-six percent of patients showing negativity for HDV-RNA (i.e. sustained viral 
response) in the HIDIT-1 trial experienced a late relapse[59]. These data prompted 
questions regarding the role of the 6-mo post-therapy negative viremia, considering its 
potential roles as a surrogate marker of HDV cure and sustained viral response[60]. 
New suggestions arose from a further sub-analysis of the HIDIT-1 trial to investigate 
positive and negative predictors of response[60]; in particular, the negative level of 
HDV-RNA at week 24 of treatment or at the end of treatment was found to identify 
responders with a prediction value of 71% or 100% respectively. Moreover, HBsAg 
kinetic parameters during treatment were proposed for monitoring response to 
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therapy, in association to the HDV-RNA. According to an Italian study, a cut-off of 
HBsAg < 1000 at month 6 of Peg-IFN therapy is able to discriminate responders and 
partial responders from non-responders[61]. Furthermore, the association of HBsAg 
reduction (0.105 Log) and HDV-RNA decrease (1.610 Log) from baseline to month 6 
was found to be predictive of HBsAg clearance.
Clinical impact of IFN-based therapy
An important end-point of HDV therapy is HDV-RNA clearance, as determined by 
sensitive assays[62]. Unfortunately, the presence of minimal residual virus that falls 
below the threshold of detection of an assay could explain reactivation in the presence 
of HBsAg. The ideal goal of therapy in HBV/HDV co-infection is the clearance of 
HBsAg; although, this is rarely achieved[63]. In any case, IFN treatment was reported 
effective in altering the disease progression-associated events[64]. The loss of HDV-
RNA during follow-up was a more frequent occurrence among the IFN-α treated 
patients and it was linked to long-term survival without complications[55,65]. Based 
on this observation, a durable undetectability of HDV viremia was proposed as a 
surrogate and more realistic end-point[64].
New therapeutic targets in HDV
Some new promising drugs have advanced in phase II clinical trials. Specifically, these 
represent inhibitors of the NTCP receptor[66] and farnesyltransferase[67] and the 
group of nucleic acid polymers[68] (Table 1).
Myrcludex B: Myrcludex B (MyrB, subsequently named bulevirtide) is a myristoylated 
synthetic peptide, containing 47 amino acids of the preS1 domain of the HBV L-surface 
protein. It is able to bind to the NTCP, which has been identified as a receptor for 
HBV/HDV entry (Figure 1)[12]. The concentration of this drug required to inhibit the 
virus is 100 times lower than that required for bile salt transport inhibition[69].
After a preliminary study[70], Bogomolov et al[71] assessed the efficacy and safety 
of MyrB in a total of 24 patients. The study design assigned 7 patients to receive the 48-
wk Peg-IFN-α treatment, 7 patients to receive 2 mg MyrB administered by subcut-
aneous injection for 24 wk followed by Peg-IFN for 48 wk, and 7 patients to receive 
MyrB and Peg-IFN for 24 wk plus an additional 24 wk of Peg-IFN. Notably, the HDV-
RNA levels decreased by at least one log in the MyrB cohort at week 24 and ALT 
normalized in 6 patients. While the decline of viremia was observed in all three 
treatment groups, HBsAg level showed no change in any.
A subsequent phase II trial enrolled 120 patients with CHD, and randomized them 
into four treatment groups. Three groups were treated with three different doses of 
MyrB (2 mg, 5 mg and 10 mg) in combination with tenofovir (245 mg/d), while one 
group was administered tenofovir alone[72]. At the end of treatment, the best result (a 
-2.7 Log decline of HDV-RNA) was found in patients who received the higher dose of 
MyrB plus tenofovir. However, for all groups, about two-thirds of the patients who 
were responders experienced relapse during the follow-up.
A new phase II study was designed to evaluate the efficacy of 2 mg and 5 mg MyrB 
combination therapy with Peg-IFN-α, and compared to Peg-IFN-α and MyrB mono-
therapies[73]. The MyrB and Peg-IFN combination yielded high rates of off-treatment 
HDV-RNA suppression and reduction in HBsAg. Recently, MyrB was authorized as 
an orphan medicine by the European Medicine Agency, making it available for usage 
in patients with HDV compensated liver disease and active viral replication.
Lonafarnib: Lonafarnib (LNF) is a farnesyl-transferase inhibitor, originally developed 
in cancer treatment. In the HDV setting, the drug inhibits the farnesylation of L-
HDAg, which is essential for interaction with HBsAg in the assembly of new viral 
particles. In a first, short-term controlled study, patients received oral LNF at 100 mg 
or 200 mg twice daily. While the drug was effective in reducing virus levels, it was 
mostly associated with gastro-intestinal adverse events and weight loss[74].
Four different subsequent trials were designed and identified as ‘LOWR-HDV’. In 
studies 1 and 2, the LNF was administered at different doses, either alone or in 
combination with ritonavir or Peg-IFN. Overall, it induced a significant viral decline
[75], with a mean log reduction of -5.57 Log10 U/mL achieved in the triple combination 
group[76]. In study 3, patients on nucleos(t)ide analogues were treated with LNF at 50 
mg/d, 75 mg/d, 100 mg/d plus ritonavir for 12 wk or 24 wk[77]. The regimen of LNF 
50 mg plus ritonavir once daily was superior, when compared to the higher doses of 
the drug. Finally, the regimen of dose escalation was tested in study 4, the LOWR-
HDV-4[78].
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Altogether, the findings from these different LOWR-HDV studies supported the 
antiviral effect of LNF. Moreover, its combination with ritonavir allowed for the use of 
lower doses and produced more manageable side effects. At present, a phase 3 clinical 
study (D-LIVR) is ongoing. This is a randomized placebo-controlled trial comparing 50 
mg LNF plus ritonavir twice per day with or without Peg-IFN-α in patients 
maintained on nucleos(t)ide analogues.
Nucleic acid polymers: Nucleic acid polymers are phosphorothioate oligonucleotides 
with antimicrobial activity, some of which have shown more specific HBV inhibiting 
properties (e.g., REP 2139). The antiviral effect seems to be related to various 
mechanisms, including the inhibition of HBsAg release and assembly and the 
interaction with both S-HDAg and L-HDAg[79,80]. REP 2139 was tested in 12 patients 
with CHD at a dose of 500 mg administered intravenously once a week for 15 wk, 
followed by a 250 mg dose combined with subcutaneous injection of 180 µg Peg-IFN 
for 15 wk and finally Peg-IFN mono-therapy given for 33 wk[81]. Nine patients, who 
became HDV-RNA-negative during treatment, remained non-viremic at the end of 
treatment and showed a mean HDV-RNA decline of 5.34 Log10 IU/L. REP 2139 
induced a remarkable HBsAg decline (3.5 Log10 IU/mL) compared to baseline. The 
most common side effects experienced by patients during treatment were thrombocyt-
openia, neutropenia and increased ALT levels. Eleven participants were followed for 
3.5 years in the REP 301-LTF study[82] and they showed a long-term safety profile as 
well as persistent virological control and functional cure.
CONCLUSION
HDV remains an important health problem worldwide. Although the infection map is 
subject to change due to diffusion of the HBV vaccine, some geographic areas are 
currently a virus reservoir. Moreover, the real burden of infection appears to be 
underestimated, both in the general and at-risk populations. It is known that HDV-
related liver disease is influenced by replicative activity of the virus, which is crucial in 
inducing cirrhosis and promoting hepatic decompensation. For this reason, the 
research for new therapeutic strategies has focused on molecules interfering with the 
replication cycle of HDV.
These novel drugs have demonstrated antiviral efficacy and tolerability, but there 
remain open questions to be answered and clarified in long-term treatment and 
follow-up. MyrB is administered via subcutaneous injection. Although it induced a 
decrease in viral loads, it did not reduce the HBsAg level. On the other hand, MyrB 
showed a good safety profile, even in some patients with compensated cirrhosis. LNF, 
on the other hand, has the advantage of oral intake. Moreover, when administered in 
combination with ritonavir, it was the determinant for reduction of gastrointestinal 
side-effects. For both drugs, viral reactivation and ALT flares were reported at the end 
of treatment. REP 2139 requires an intravenous administration. It produced a rapid 
reduction in HBsAg levels, and not only in HDV viremia, in a lasting way; however, 
this effect needs to be tested on larger numbers of patients.
In conclusion, MyrB, LNF and REP 2139 represent expected and promising 
therapeutic options for HDV infection. Further studies are needed to define the utility 
of combination therapy with IFN.
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